Jennifer Amengual, MD
Enriched profileHerbert Irving Associate Professor of Medicine, Division of Hematology and Oncology · Columbia University Irving Medical Center
Jennifer Amengual is Herbert Irving Associate Professor of Medicine, Division of Hematology and Oncology at Columbia University Irving Medical Center. OpenAlex indexes 211 publications with 2,348 citations (h-index 23); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 24 Oct 2026
Jennifer Effie Amengual, M.D., is Herbert Irving Associate Professor of Medicine, Division of Hematology and Oncology at Columbia University Irving Medical Center. The public record shows 211 publications with 2,348 citations (h-index 23), centered on Lymphoma Diagnosis and Treatment, Histone Deacetylase Inhibitors Research, Viral-associated cancers and disorders. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 15 companies, 2 NIH-funded awards (2018–2026).
- Top research focus: Lymphoma Diagnosis and Treatment
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 43.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
Sponsor: Jennifer Amengual
- Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Sponsor: Jennifer Amengual
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Sponsor: SWOG Cancer Research Network
Industry payments
Updated 24 Oct 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20251 payment
- PFIZER INC.Program year20251 payment
- Epizyme, Inc.Program year20251 payment
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
83.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor33.8%Valacyclovir100%Part D<11 patientsAzole Antifungal27.3%Fluconazole100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
16.9%Serotonin-3 Receptor Antagonist16.9%Ondansetron Odt100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 24 Oct 2026
2 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Columbia University NCI Community Oncology Research Program
Columbia University Health Sciences
FY2026$1,049,702UG1CA189960 - Columbia University NCI Community Oncology Research Program
Columbia University Health Sciences
FY2025$1,008,906UG1CA189960 - Columbia University Minority/Underserved Site NCI Community Oncology Research Program
Columbia University Health Sciences
FY2024$980,169UG1CA189960
Congress activity
Updated 24 Oct 2026
49 congress contributions (2012–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Overcoming resistance to bispecific antibodies through epigenetic priming in B-cell lymphoma
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Most-cited works
by citation count (OpenAlex)- 01Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionArticle169 citations2017
- 02
- 03
- 04
- 05
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 24 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jennifer-amengual-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
doctors.columbia.edu/us/ny/new-york/jennifer-effie-amengual-md-161-fort-washington-avenue
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctors.columbia.edu ↗ - Other
cancer.columbia.edu/node/61
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
New York Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗ - Degree in Nutritional Sciences
Cornell University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
Editorial & leadership roles
journal and society appointments- Editorial Board Member
Clinical Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irvinginstitute.columbia.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →gendermed.org ↗
Secondary affiliations
appointments beyond the home institution- Center for Lymphoid Malignancies
Columbia University Irving Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Rebecca Hahn, MD
Columbia University Irving Medical Center
Susheel Kodali, MD
Columbia University Irving Medical Center
Ronald Wapner, MD
Columbia University Irving Medical Center
Lawrence Honig, MD
Columbia University Irving Medical Center
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Thomas Witzig, MD
Mayo Clinic
Wyndham Wilson, MD
National Cancer Institute (NCI)